(1)
PRS stratifies disease risk and brings precision medicine into clinical routine
Allelica, a leading genomics software company specialising in developing polygenic risk scores (PRSs) for common diseases, today announced that the company has raised $1.75 million in a seed financing round led by Valor Ventures, Sternberg Health, Pi Campus, as well as strategic business angels also participated in the round. As part of the transaction, Valor Ventures General Partner Gary Peat has joined the Allelica board of directors and Allelica has relocated its headquarters to New York City.
The proceeds of the financing will be used to advance clinical integration of Allelica s PRS software into healthcare systems in the US. A PRS is a measurement of a person s risk of disease based on their genes and is based on combining the effects of a large number of genetic variants across the genome. This information can be used to stratify individuals based on their risk of disease. By combining PRS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Addex Reports Full Year 2020 Financial Results and Provides Corporate Update
Addex TherapeuticsMarch 11, 2021 GMT
Strong cash and cash equivalents position at Dec 31, 2020 of $20.2M (CHF18.7M)
Balance sheet further strengthened by $11.5M fundraising on January 11, 2021
Three clinical studies in neurology programs expected to start during H1 2021
Clinical stage neurology programs aimed at large underserved market opportunities (Epilepsy, Parkinson’s disease LID and Blepharospasm)
Geneva, Switzerland, March 11, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the full-year ended December 31, 2020 and provided a corporate update.
About Addex Therapeutics:
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional orthosteric small molecule or biological drugs. Addex s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant s therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be init
SUVs have been named crowned Car of the Year by two different sets of motoring experts.
Carsales has awarded its prestigious prize to the Kia Sorento while Wheels has given its annual prize to the Mazda CX-30.
Last year, for the first time ever, the majority of cars sold in Australia were an SUV with higher ground clearance.
The category includes both front-wheel drive and all-wheel drive variants with virtually every major car manufacturer - from the budget to the super luxury - offering an SUV.
SUVs have been named crowned Car of the Year by two different sets of motoring experts. Carsales has awarded its prestigious prize to the Kia Sorento
Kia Sorento named 2020 carsales Car of the Year motoring.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from motoring.com.au Daily Mail and Mail on Sunday newspapers.